bsc.news
Avalanche's C-Chain has quietly outpaced most of the Layer-1 market over the past year. Daily transactions have climbed roughly 10x since April 2025, daily active users now sit above 600,000, and three U.S. spot $AVAX ETFs have launched in the same window. The chain is busy while the market looks elsewhere.
Data from Artemis shows the C-Chain processing 2.5 million to 3 million daily transactions in early 2026, with a peak of 3.6 million on April 6. That is a sharp move from the low hundreds of thousands recorded twelve months earlier.
How big is the transaction surge?
Artemis data puts three-year growth in daily active users at 1,369%. The weekly chart backs it up. Weekly transactions climbed from roughly 5 million in mid-2025 to more than 20 million by late January 2026. Daily active users crossed 600,000 in the same period and have held there since.
Current snapshot numbers from DefiLlama back the trend:
- Active addresses (24h): 634,657
- Chain fees (24h): $5,027
- Stablecoin market cap: $1.54 billion, up 10.89% over 7 days
- DEX volume (24h): $155.91 million
- TVL: $739.7 million
- $AVAX price: ~$9.54
The growth is not bot traffic, according to Nansen. Non-Sybil addresses have climbed from roughly 5,000 to 49,000 over the past four months, suggesting real wallets are showing up and staying.
Who is actually using Avalanche?
The busiest applications on the C-Chain over the past 30 days, measured by gas fees paid, are a mix of DEXs, stablecoin issuers, and wallet infrastructure. Paraswap leads with $2,179 in gas fees, followed by Tether at $988 and Trader Joe at $699. Circle, LFJ, Metamask, Uniswap, Maplestory, Odos, and Binance round out the top ten.
Stablecoin activity is doing serious work here. Artemis-tracked stablecoin transfer volume, which excludes MEV and intra-CEX flows, is up 614% over three years. Total stablecoin transfer volume is up 631% in the same window.
The takeaway: DeFi rails and stablecoin flow are the engine, not memecoin speculation.
What is driving the institutional capital?
The onchain spike lines up with an aggressive ETF calendar. VanEck launched its spot $AVAX ETF (VAVX) on Nasdaq in January 2026, giving U.S. investors their first direct spot exposure. Grayscale followed in March with its $AVAX Staking ETF (GAVA), converting its existing trust and adding staking yield.
Bitwise launched the latest product, BAVA, on NYSE on April 15. It is the first U.S. $AVAX ETF with built-in staking, aimed at allocators looking for regulated yield exposure. CME Group is also preparing $AVAX futures, with a planned May 4, 2026 launch pending regulatory review.
Nansen flagged three catalysts behind the activity surge: the GAVA launch, opening a regulated lane for institutional capital, SEC and CFTC classification of $AVAX as a digital commodity, and Broadridge bringing proxy voting onchain.
What happens next?
Three ETFs in four months, a futures product on deck, and onchain metrics still rising for@avax. The open question is whether the current transaction floor holds once early ETF inflows cool off.
Annualized revenue on the C-Chain is down 39.2% year-over-year despite the activity spike, a side effect of the Avalanche9000 upgrade that cut base fees. Lower fees helped onboard users but squeezed chain revenue. That trade-off is worth watching as more subnets and applications launch on top of the cheaper fee environment.
Avalanche is one of the strongest-performing layer-1 chains by raw usage, and the market is starting to notice.
Sources:
- Artemis - Onchain data platform, primary source for C-Chain transaction and active user growth and stablecoin transfer volume.
- DefiLlama - TVL, chain fees, DEX volume, active addresses, and stablecoin market cap snapshot.
- VanEck - January 26, 2026 press release on the VAVX spot $AVAX ETF launch on Nasdaq.
- Grayscale - March 12, 2026 launch of the GAVA $AVAX Staking ETF on Nasdaq.
- Bitwise - April 15, 2026 launch of the BAVA spot Avalanche ETP on NYSE with in-house staking.
- CME Group - Planned May 4, 2026 launch of $AVAX and SUI futures pending regulatory review.